Trials / Terminated
TerminatedNCT01331109
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 13 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Milnacipran | maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-04-07
- Last updated
- 2013-09-30
- Results posted
- 2013-09-30
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01331109. Inclusion in this directory is not an endorsement.